AR050200A1 - Anticuerpos antagonistas de il-17 - Google Patents

Anticuerpos antagonistas de il-17

Info

Publication number
AR050200A1
AR050200A1 ARP050103256A ARP050103256A AR050200A1 AR 050200 A1 AR050200 A1 AR 050200A1 AR P050103256 A ARP050103256 A AR P050103256A AR P050103256 A ARP050103256 A AR P050103256A AR 050200 A1 AR050200 A1 AR 050200A1
Authority
AR
Argentina
Prior art keywords
human
binding molecule
production
antibody
activity
Prior art date
Application number
ARP050103256A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR050200A1 publication Critical patent/AR050200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP050103256A 2004-08-05 2005-08-04 Anticuerpos antagonistas de il-17 AR050200A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound

Publications (1)

Publication Number Publication Date
AR050200A1 true AR050200A1 (es) 2006-10-04

Family

ID=32982602

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103256A AR050200A1 (es) 2004-08-05 2005-08-04 Anticuerpos antagonistas de il-17

Country Status (40)

Country Link
US (9) US7807155B2 (h)
EP (5) EP2364729B3 (h)
JP (1) JP4682200B2 (h)
KR (2) KR20080029018A (h)
CN (1) CN101001645B (h)
AR (1) AR050200A1 (h)
AT (1) ATE517924T1 (h)
AU (2) AU2005268857C1 (h)
BE (1) BE2015C041I2 (h)
BR (3) BR122018075556B1 (h)
CA (1) CA2573586C (h)
CY (6) CY1111963T1 (h)
DK (4) DK1776142T6 (h)
EC (1) ECSP077198A (h)
ES (4) ES2536228T3 (h)
FR (1) FR15C0048I2 (h)
GB (1) GB0417487D0 (h)
HK (1) HK1256639A1 (h)
HR (3) HRP20110758T4 (h)
HU (4) HUE038187T2 (h)
IL (1) IL180717A (h)
LT (3) LT2902039T (h)
LU (2) LU92768I2 (h)
MA (1) MA28982B1 (h)
MX (1) MX2007001338A (h)
MY (1) MY144925A (h)
NL (1) NL300749I2 (h)
NO (9) NO336279B1 (h)
NZ (1) NZ552658A (h)
PE (1) PE20060418A1 (h)
PL (4) PL2364729T6 (h)
PT (4) PT2902039T (h)
RU (2) RU2426741C3 (h)
SG (1) SG155186A1 (h)
SI (4) SI1776142T1 (h)
TN (1) TNSN07034A1 (h)
TR (1) TR201808057T4 (h)
TW (1) TWI359153B (h)
WO (1) WO2006013107A1 (h)
ZA (1) ZA200700242B (h)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1933869T3 (pl) 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
NZ569910A (en) 2005-12-20 2012-06-29 Sbi Biotech Co Ltd Anti-ILT7 antibody
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2007117749A2 (en) * 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
PE20080739A1 (es) * 2006-08-11 2008-06-14 Schering Corp Anticuerpos para il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
WO2008106131A2 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
KR102606597B1 (ko) 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
EP2171449A2 (en) * 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AU2009204441B2 (en) * 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2009133103A1 (en) * 2008-04-29 2009-11-05 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
MX2010012090A (es) 2008-05-05 2011-04-11 Novimmune Sa Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos.
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
ES2493042T3 (es) * 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
CN102781470B (zh) 2009-03-05 2016-01-20 Abbvie公司 Il-17结合蛋白
PT2424895T (pt) * 2009-04-27 2017-12-15 Novartis Ag Composições e métodos para aumentar o crescimento muscular
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
CA2772628A1 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2485763A4 (en) * 2009-10-10 2013-10-30 Univ Leland Stanford Junior CYTOKINE COMPOSITIONS OF THE IL-17 FAMILY AND ITS USES
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EA029283B1 (ru) 2009-10-30 2018-03-30 Янссен Байотек, Инк. Антагонисты il-17a
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
EP2601217B1 (en) * 2010-08-05 2017-06-14 AnaptysBio, Inc. Antibodies directed against il-17
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2862955T5 (en) 2010-10-01 2025-01-29 Modernatx Inc Engineered nucleic acids and methods of use thereof
US9717791B2 (en) * 2010-10-08 2017-08-01 Novartis Ag Methods of treating psoriasis using IL-17 antibody
KR20180019247A (ko) * 2010-11-05 2018-02-23 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
WO2012095507A1 (en) * 2011-01-13 2012-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
US8580265B2 (en) 2011-01-14 2013-11-12 Ucb Pharma S.A. Antibody molecules which bind IL-17A and IL-17F
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
US9624261B2 (en) 2011-03-29 2017-04-18 Glaxosmithkline Llc Buffer system for protein purification
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4015005A1 (en) 2011-10-03 2022-06-22 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2856252A1 (en) 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868438A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PE20142422A1 (es) 2012-04-05 2015-01-21 Hoffmann La Roche Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
CA2870025A1 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
TWI632159B (zh) 2013-02-08 2018-08-11 諾華公司 抗－ｉｌ－１７ａ抗體及其於治療自體免疫及發炎病症之用途
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
JP6255099B2 (ja) 2013-08-15 2017-12-27 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
CN118178647A (zh) 2013-08-30 2024-06-14 武田药品工业株式会社 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3670533A1 (en) 2013-11-18 2020-06-24 Shanghai Hengrui Pharmaceutical Co. Ltd. Il-17a binding agent and uses thereof
US20160340422A1 (en) * 2014-01-28 2016-11-24 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
BR112017003332A2 (pt) 2014-09-10 2017-11-28 Novartis Ag uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
DK3245224T3 (da) 2015-01-12 2020-09-21 Affibody Ab Il-17a-bindende polypeptider
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MA42444A (fr) 2015-07-16 2018-05-23 Lilly Co Eli Traitement du prurit
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
IL297775A (en) 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
SG10202008769SA (en) 2016-03-10 2020-10-29 Viela Bio Inc Ilt7 binding molecules and methods of using the same
ES2987504T3 (es) 2016-03-10 2024-11-15 Acceleron Pharma Inc Proteínas de unión al receptor de activina de tipo 2 y usos de las mismas
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
CN109476733A (zh) 2016-07-19 2019-03-15 诺华股份有限公司 使用il-17拮抗剂治疗新发斑块型银屑病的方法
PE20191075A1 (es) 2016-09-14 2019-08-20 Beijing hanmi pharm co ltd Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
AU2018217816A1 (en) 2017-02-10 2019-08-15 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
KR20200083996A (ko) 2017-11-02 2020-07-09 노파르티스 아게 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
WO2019191563A1 (en) * 2018-03-29 2019-10-03 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
US12134644B2 (en) 2018-07-31 2024-11-05 Weiqun SHEN Anti-IL-17A antibodies and use thereof
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
MA54857A (fr) 2019-01-31 2021-12-08 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
AU2020284114B2 (en) * 2019-05-31 2025-06-26 Fibrobiologics, Inc. Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
MX2022001068A (es) 2019-07-26 2022-02-14 Sinocelltech Ltd Anticuerpo anti-il17a humanizado y uso del mismo.
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
KR20220070244A (ko) * 2019-09-25 2022-05-30 도꾜 다이가꾸 전신성 강피증 치료용 의약 조성물
US20220365100A1 (en) 2019-09-30 2022-11-17 Janssen Pharmaceutica Nv Compositions and methods for an il-17 target engagement assay with large molecule modulators
IL292926A (en) 2019-11-19 2022-07-01 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
WO2021111377A2 (en) 2019-12-06 2021-06-10 Novartis Ag Methods of treating lichen planus using interleukin-17 (il-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
IL298882A (en) 2020-06-23 2023-02-01 Novartis Ag Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022117773A1 (en) 2020-12-02 2022-06-09 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
CA3205650A1 (en) 2020-12-22 2022-06-30 Novartis Ag Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
EP4526299A1 (en) 2022-04-25 2025-03-26 Novartis AG Crystalline forms of an il-17 inhibitor
EP4525984A1 (en) 2022-05-16 2025-03-26 Novartis AG Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
KR20250011948A (ko) 2022-05-18 2025-01-22 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
AU696775B2 (en) 1995-03-23 1998-09-17 Kirin-Amgen, Inc. IL-17 receptor
EP0839196B1 (en) * 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DK0862454T3 (da) 1995-10-27 2002-12-30 Schering Corp CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
DE69841140D1 (de) 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
AU760035B2 (en) 1997-11-10 2003-05-08 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
AU2004799A (en) 1997-12-19 1999-07-12 Millennium Biotherapeutics, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
WO1999035263A2 (en) 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
EP1056842A2 (en) 1998-02-11 2000-12-06 Maxygen, Inc. Genetic vaccine vector engineering
ATE365800T1 (de) 1998-05-15 2007-07-15 Genentech Inc Therapeutische verwendungen von il-17 homologe polypeptide
CA2343569C (en) 1998-09-17 2010-09-14 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
ATE531801T1 (de) 1999-01-11 2011-11-15 Schering Corp Interleukin-17-verwandte säugetier-cytokine, polynukleotide, die diese kodieren und deren verwndung
WO2000042187A1 (en) 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
DE60040651D1 (de) 1999-02-12 2008-12-11 Emd Serono Res Ct Inc Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
EP1326974B1 (en) 2000-10-13 2006-12-27 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
WO2002102411A2 (en) 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
MXPA05012571A (es) * 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
EP2974742A1 (en) 2003-11-21 2016-01-20 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting il-17 activity
WO2005108616A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
PL1933869T3 (pl) * 2005-09-01 2010-06-30 Merck Sharp & Dohme Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu

Also Published As

Publication number Publication date
US7807155B2 (en) 2010-10-05
DK2902039T3 (en) 2018-07-16
RU2426741C3 (ru) 2017-11-15
DK1776142T3 (da) 2011-10-31
NO20070985L (no) 2007-03-30
PL2364729T3 (pl) 2014-10-31
NO20150065L (no) 2007-03-30
LTC1776142I2 (lt) 2022-07-11
AU2005268857B2 (en) 2010-01-28
PT2366405E (pt) 2015-06-30
HUE025815T2 (en) 2016-04-28
US8119131B2 (en) 2012-02-21
NL300749I2 (nl) 2017-11-02
NZ552658A (en) 2009-11-27
BE2015C041I2 (h) 2024-10-08
EP1776142A1 (en) 2007-04-25
US20170355762A1 (en) 2017-12-14
BRPI0513078A (pt) 2008-04-22
NO2015023I1 (no) 2015-11-02
TWI359153B (en) 2012-03-01
US20100215666A1 (en) 2010-08-26
US20120107325A1 (en) 2012-05-03
CA2573586A1 (en) 2006-02-09
EP2366405A3 (en) 2012-01-18
AU2010201689B2 (en) 2011-09-29
SI2364729T1 (sl) 2014-08-29
ES2536228T3 (es) 2015-05-21
RU2426741C2 (ru) 2011-08-20
ECSP077198A (es) 2007-02-28
NO2016017I1 (no) 2016-08-23
SI1776142T1 (sl) 2011-11-30
EP2902039B1 (en) 2018-04-11
CA2573586C (en) 2013-06-25
KR100852523B9 (ko) 2025-03-28
EP2364729A2 (en) 2011-09-14
NO348010B1 (no) 2024-06-17
BRPI0513078B1 (pt) 2019-02-19
EP2364729B1 (en) 2014-05-14
LTPA2015029I1 (lt) 2022-07-11
CN101001645A (zh) 2007-07-18
BRPI0513078B8 (pt) 2019-08-27
FR15C0048I1 (fr) 2015-08-28
PL2366405T3 (pl) 2015-08-31
PE20060418A1 (es) 2006-06-15
IL180717A0 (en) 2007-06-03
US20250122277A1 (en) 2025-04-17
ES2677245T3 (es) 2018-07-31
HUE038187T2 (hu) 2018-10-29
SI2902039T1 (en) 2018-07-31
NO2018007I1 (no) 2018-02-14
LT2902039T (lt) 2018-06-25
KR20080029018A (ko) 2008-04-02
DK2366405T3 (en) 2015-05-11
EP1776142B3 (en) 2015-06-24
BR122017009404B1 (pt) 2022-02-22
IL180717A (en) 2012-07-31
MX2007001338A (es) 2008-03-11
EP2364729A3 (en) 2012-01-18
ES2487533T7 (es) 2015-07-14
NO337129B1 (no) 2016-01-25
LU92768I2 (fr) 2015-11-03
HRP20110758T1 (en) 2011-11-30
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
TR201808057T4 (tr) 2018-06-21
HRP20150480T1 (hr) 2015-07-17
CY1116256T1 (el) 2017-02-08
PT1776142E (pt) 2011-10-06
MA28982B1 (fr) 2007-11-01
ES2487533T3 (es) 2014-08-21
EP3409288A1 (en) 2018-12-05
DK2364729T3 (da) 2014-07-21
NO20151787L (no) 2006-02-06
ES2367440T3 (es) 2011-11-03
PL2902039T3 (pl) 2018-09-28
NO341384B1 (no) 2017-10-30
FR15C0048I2 (fr) 2015-11-20
ES2367440T7 (es) 2015-07-14
HRP20110758T4 (hr) 2015-07-31
AU2005268857A1 (en) 2006-02-09
AU2005268857C1 (en) 2012-01-19
US20190270804A1 (en) 2019-09-05
KR20070036166A (ko) 2007-04-02
PT2902039T (pt) 2018-07-17
SG155186A1 (en) 2009-09-30
US20140079719A1 (en) 2014-03-20
EP1776142B9 (en) 2016-09-07
RU2011113153A (ru) 2012-10-20
MY144925A (en) 2011-11-30
TNSN07034A1 (en) 2008-06-02
PL1776142T3 (pl) 2011-12-30
CY2018027I2 (el) 2020-05-29
NO336279B1 (no) 2015-07-06
US8617552B2 (en) 2013-12-31
EP1776142B1 (en) 2011-07-27
WO2006013107A1 (en) 2006-02-09
PL2364729T6 (pl) 2016-06-30
CY2015030I2 (el) 2017-11-14
HK1101277A1 (en) 2007-10-12
NO20171697A1 (no) 2007-03-30
LUC00088I2 (h) 2018-12-17
HRP20181069T1 (hr) 2018-09-07
CY2018027I1 (el) 2020-05-29
NO2015023I2 (no) 2015-10-26
ZA200700242B (en) 2008-08-27
EP2366405B1 (en) 2015-02-25
HUS1500037I1 (hu) 2017-10-30
NO20150064L (no) 2007-03-30
ES2367440T9 (es) 2021-04-28
US20230235038A1 (en) 2023-07-27
PL1776142T4 (pl) 2018-04-30
CY1120723T1 (el) 2019-12-11
PT2364729E (pt) 2014-09-01
LTPA2018515I1 (lt) 2018-10-25
AU2010201689A1 (en) 2010-05-20
CY1115444T1 (el) 2017-01-04
GB0417487D0 (en) 2004-09-08
US20090280131A1 (en) 2009-11-12
AU2005268857B8 (en) 2010-05-27
BR122018075556B1 (pt) 2022-10-18
DK1776142T6 (en) 2015-07-06
JP2008507988A (ja) 2008-03-21
SI2366405T1 (sl) 2015-07-31
BRPI0513078C1 (pt) 2021-05-25
DK2364729T6 (en) 2015-07-06
KR100852523B1 (ko) 2008-08-14
CY2015030I1 (el) 2015-11-04
CN101001645B (zh) 2012-09-05
TW200617025A (en) 2006-06-01
PL1776142T6 (pl) 2016-06-30
HUS1800040I1 (hu) 2018-11-28
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
CY1111963T1 (el) 2015-11-04
EP2902039A1 (en) 2015-08-05
EP2366405A2 (en) 2011-09-21
HK1256639A1 (en) 2019-09-27
EP2364729B3 (en) 2015-06-24
JP4682200B2 (ja) 2011-05-11
US10344084B2 (en) 2019-07-09
HK1207559A1 (en) 2016-02-05
NO337286B1 (no) 2016-02-29
ATE517924T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
AR050200A1 (es) Anticuerpos antagonistas de il-17
AR027253A1 (es) Anticuerpos para il-1beta humana
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
CY1121072T1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
CY1119964T1 (el) Αναστολεις οδου σηματοδοτησης notch και χρηση αυτων στη θεραπευτικη αγωγη καρκινων
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CR9209A (es) Anticuerpos frente al receptor alfa-1 de la il-13 y usos de los mismos
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
AR038953A1 (es) Anticuerpos humanizados que reconocen el peptido amiloide beta
CY1116291T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17
PE20141548A1 (es) Anticuerpo anti-alfabeta tcr
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
AR044580A1 (es) Anticuerpos humanizados que reconocen el peptido beta amiloideo
PE20081501A1 (es) Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos
SI2970447T1 (en) PROTITELES AGAINST PAN-ELR + CXC KEMOCIN
SI2718320T1 (en) Molecules that bind anti-Pseudomonas psl and their use
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
PE20121687A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
EA201291161A3 (ru) Связывающие csf1r антитела
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EA200900037A1 (ru) Моноклональные антитела против интерлейкина-6 (il-6) и их применение
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
NZ598063A (en) Gram-positive bacteria specific binding compounds
AR085624A2 (es) Anticuerpos de p-caderina
AR085955A1 (es) Proteinas de union al antigeno

Legal Events

Date Code Title Description
FG Grant, registration